Clicky

AXOGEN INC. DL -01(LT3)

Description: Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.


Keywords: Surgery Neurosurgery Neurophysiology Nerve Surgical Site Submucosa Axogen Nerve Allograft Neuroregeneration Peripheral Nerve Injuries

Home Page: www.axogeninc.com

13631 Progress Boulevard
Alachua, FL 32615
United States
Phone: 386 462 6800


Officers

Name Title
Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A. Chief Financial Officer
Ms. Karen Zaderej Advisor
Mr. Erick DeVinney Chief Innovation Officer
Mr. Todd Puckett Vice President of Operations
Mr. Harold D. Tamayo Vice President of Finance & Investor Relations
Mr. Marc A. Began Executive VP, General Counsel & Chief Compliance Officer
Ms. Doris Quackenbush Vice President of Sales
Mr. Jens Schroeder Kemp Chief Marketing Officer
Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 40.3226
Trailing PE: 0
Price-to-Book MRQ: 6.4201
Price-to-Sales TTM: 3.3958
IPO Date:
Fiscal Year End: December
Full Time Employees: 426
Back to stocks